Aromatase inhibitors, when compared with tamoxifen, show an increased risk of arterial events as myocardial infarction and angina, which must be interpreted in the context of the protective effect of tamoxifen [22, 25]. The gene discussed is CYP19A1; the disease is myocardial infarction.